Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
8.12
-0.32 (-3.79%)
Mar 5, 2026, 4:00 PM EST - Market closed
Passage Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 19.88 | 24.99 | 41.58 | 45.54 | 60.06 | |
| Research & Development | 23.28 | 40.18 | 61.42 | 83.75 | 117.67 | |
| Operating Expenses | 43.15 | 65.17 | 103 | 129.29 | 177.73 | |
| Operating Income | -43.15 | -65.17 | -103 | -129.29 | -177.73 | |
| Interest & Investment Income | - | 4.3 | 5.6 | 2.3 | 3.12 | |
| Other Non Operating Income (Expenses) | 3.77 | 1.33 | 0.73 | -0.03 | - | |
| EBT Excluding Unusual Items | -39.38 | -59.53 | -96.67 | -127.03 | -174.61 | |
| Merger & Restructuring Charges | - | - | - | -6.1 | - | |
| Gain (Loss) on Sale of Investments | - | - | - | - | -2.78 | |
| Asset Writedown | -6.15 | -5.23 | -5.39 | - | - | |
| Pretax Income | -45.52 | -64.77 | -102.06 | -136.13 | -185.39 | |
| Net Income | -45.52 | -64.77 | -102.06 | -136.13 | -185.39 | |
| Net Income to Common | -45.52 | -64.77 | -102.06 | -136.13 | -185.39 | |
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | |
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | |
| Shares Change (YoY) | 5.05% | 10.34% | 0.58% | 2.03% | 38.14% | |
| EPS (Basic) | -14.35 | -21.44 | -37.29 | -50.02 | -69.51 | |
| EPS (Diluted) | -14.35 | -21.44 | -37.29 | -50.02 | -69.51 | |
| Free Cash Flow | -31.51 | -47.99 | -78.41 | -120.48 | -144.52 | |
| Free Cash Flow Per Share | -9.93 | -15.89 | -28.65 | -44.27 | -54.19 | |
| EBITDA | -42.42 | -62.09 | -99.28 | -125.62 | -176.19 | |
| D&A For EBITDA | 0.73 | 3.08 | 3.72 | 3.68 | 1.54 | |
| EBIT | -43.15 | -65.17 | -103 | -129.29 | -177.73 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.